
Please try another search
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance. The company is based in Calgary, Canada.
Name | Age | Since | Title |
---|---|---|---|
Raymond Pratt | - | 2021 | Independent Director |
Allen Warren Davidoff | 65 | 2018 | Founder, CEO, President & Director |
Paul Joseph Van Damme | 75 | 2018 | Independent Director |
Anthony J. Giovinazzo | 68 | 2022 | Independent Chair of the Board |
Ronald Perrone | - | 2024 | Member of Clinical Advisory Board |
Abigail L. Jenkins | 49 | 2024 | Director |
Petter Bjornstad | - | 2018 | Member of Clinical Advisory Board |
Raymond Dennis Pratt | 74 | 2021 | Independent Director |
Henk E. D. J. ter Keurs | - | - | Member of Scientific Advisory Board |
William J. Farley | 71 | 2021 | Independent Director |
Federico Maese | - | 2018 | Member of Clinical Advisory Board |
Richard J. Johnson | - | - | Member of Clinical Advisory Board |
Anjay Rastogi | - | 2020 | Member of the Clinical Advisory Board |
Charles Edelstein | - | 2021 | Member of the Advisory Board |
Patrick A. Treanor | 57 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review